The combination of IDO inhibitor epacadostat and pembrolizumab produced an objective response rate (ORR) of 56% and a disease control rate (DCR) of 71% in untreated melanoma patients in phase I/II of the ECHO-202/KEYNOTE-037 trial. This evidence concerns the gene IDO1 and melanoma.